Kristen Fortney, Ph.D. Chief Executive Officer BioAge Labs, Inc. 1445A South 50th Street Richmond, California 94804

comment.

Re: BioAge Labs, Inc.
Registration Statement on Form S-1
Filed September 3, 2024
File No. 333-281901
Dear Kristen Fortney Ph.D.:

We have reviewed your registration statement and have the following

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe this comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to this letter, we may have additional comments.

Registration Statement on Form S-1 Certain Relationships and Related Party Transactions Directed Share Program, page 190

1. We note your disclosure here and elsewhere in your prospectus discussing your directed

share program. Please expand your disclosure here, and elsewhere as appropriate, to

address the process that prospective participants will follow to participate in the program,

the manner in which you will communicate with participants and determine the amount

each will receive, when and how you will determine the allocation for the program, and

whether such allocation will change depending on the interest level of potential $\ensuremath{\mathsf{I}}$

participants, as well as any other material features of the program. September 6, 2024 Page 2 $\,$

We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement.

Please contact Eric Atallah at 202-551-3663 or Vanessa Robertson at 202-551-3649 if you have questions regarding comments on the financial statements and related matters. Please contact Jimmy McNamara at 202-551-7349 or Joshua Gorsky at 202-551-7836 with any other questions.

Sincerely,

Division of

Corporation Finance

Office of Life

Sciences

cc: Julia Forbess